The trademark application OMJJARA was filed by GlaxoSmithKline LLC, a Limited Liability Company (the "Applicant"). The application was published for oppositions on July 7, 2022, and it was registered by office on October 14, 2022 without any oppositions.
The application was filed in English (German was selected as the second language).
Change of name and address of the trademark registration was recorded on June 13, 2022. Appointment and Replacement of representative of the trademark registration was recorded on October 16, 2022. Change of name and address of the trademark registration was recorded on October 19, 2022. Change of name and address of the trademark registration was recorded on February 1, 2023. A transfer of the trademark registration was recorded on March 23, 2023. Change of name and address of the trademark registration was recorded on July 13, 2023.
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceutical preparations and drugs for the treatment of cancer, namely, Myelofibrosis (MF)
Pharmaceutical preparations and drugs for the treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases and/or disorders
Biological and chemical preparations for the treatment of cancer
Pharmaceutical products, preparations, and compounds for the prevention and treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases and/or disorders
Pharmaceutical preparations and substance for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders
Medical reagents
Medical diagnostic reagents, assays, and test kits for testing of body fluids
Cells, protein molecules, and molecular compounds in the nature of drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals for medical purposes
DNA damage response assets, namely, pharmaceutical preparations for the treatment of conditions associated with DNA damage, namely cancer, for medical use.
The mark was filed in class 42 with following description of goods:
Pharmaceutical research and development
Development of pharmaceutical preparations and drugs
Development of pharmaceutical preparations and drugs for the treatment of blood diseases, bone and bone marrow diseases, and cancers
Scientific research and development
Scientific laboratory services
Medical laboratory services
Conducting clinical trials for others
Conducting clinical trial for others regarding pharmaceutical preparations and drugs in the field of blood diseases, bone and bone marrow diseases, and cancers
DNA screening and analysis services for scientific research purposes.
The mark was filed in class 44 with following description of goods:
Medical services
Medical testing services
DNA screening and analysis services for medical purposes.